Novartis Receives Third FDA Approval For Oral Fabhalta® (Iptacopan) - The First And Only Treatment Approved In C3 Glomerulopathy (C3G)
Phase III study showed sustained proteinuria reduction at one year with favorable safety1 <li /> Fabhalta is the only or ...